CD22 and B-cell acute lymphoblastic leukemia: Clinically, the anti-CD22 monoclonal antibody SM03 has shown efficacy in Phase III trials by disrupting CD22-SHP1-mediated NF-κB suppression, restoring B cell responsiveness in malignancies [117], while CD22-targeted CAR-T therapy demonstrates potent activity against B-cell acute lymphoblastic leukemia [118].